Skip to content

Clinical trials

Renal Insufficiency, Chronic trials in Italy with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Renal Insufficiency, Chronic Phase: Not applicable Country / region: Italy Clear all

23 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20101
20121
20141
20173
20182
20191
20202
20211
20224
20231
20242
20251
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed10
Unknown status5
Recruiting4
Not yet recruiting2
Active, not recruiting1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Federico II University3
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari2
Mario Negri Institute for Pharmacological Research2
Meyer Children's Hospital IRCCS2
Advice Pharma Group srl1
Azienda Sanitaria ASL Avellino 21
Biogem s.c.ar.l.1
Casa di Cura Dott. Pederzoli1
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico1
IRCCS Azienda Ospedaliero-Universitaria di Bologna1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Renal Insufficiency, Chronic23
Kidney Failure, Chronic4
Hypertension2
Kidney Diseases2
Acute Kidney Injury1
Albuminuria1
Anxiety Disorders1
Arteriovenous Fistula1
Cardiovascular Diseases1
Cognitive Dysfunction1

Trials

Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.